Role of uroguanylin, a peptide with natriuretic activity, in rats with experimental nephrotic syndrome

Journal of the American Society of Nephrology

Volumn 16, Issue 2, 2005, Pages 392-397

  Kikuchi, Masao ^a   Fujimoto, Shouichi ^a   Fukae, Hiroko ^a   Kinoshita, Hiroshi ^a   Kita, Toshihiro ^a   Nakazato, Masamitsu ^a   Eto, Tanenao ^a  

^a UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; PUROMYCIN AMINONUCLEOSIDE; SODIUM; UROGUANYLIN; ATRIAL NATRIURETIC FACTOR; BIOLOGICAL MARKER; NATRIURETIC FACTOR; PEPTIDE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; KIDNEY; KIDNEY PERFUSION; MALE; NATRIURESIS; NEPHROTIC SYNDROME; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; SMALL INTESTINE; SODIUM EXCRETION; SODIUM RETENTION; URINARY EXCRETION; ANIMAL; COMPARATIVE STUDY; DISEASE MODEL; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROBABILITY; RADIOIMMUNOASSAY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT; URINE;

ANIMALS; ATRIAL NATRIURETIC FACTOR; BASE SEQUENCE; BIOLOGICAL MARKERS; DISEASE MODELS, ANIMAL; MALE; MOLECULAR SEQUENCE DATA; NATRIURESIS; NATRIURETIC PEPTIDES; NEPHROTIC SYNDROME; PEPTIDES; PROBABILITY; PUROMYCIN AMINONUCLEOSIDE; RADIOIMMUNOASSAY; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 20544474271     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2004040324     Document Type: Article

References (28)

1. Forte LR, London RM, Freeman RH, Krause WJ: Guanylin peptides: Renal actions mediated by cyclic GMP. Am J Physiol Renal Physiol 278: F180-F191, 2000
2. Fonteles MC, Greenberg RN, Monteiro HSA, Currie MG, Forte LR: Natriuretic and kaliuretic activities of guanylin and uroguanylin in the isolated perfused rat kidney. Am J Physiol 275: F191-F197, 1998
3. Greenberg RN, Hill M, Crytzer J, Krause WJ, Eber SL, Hamra FK, Forte LR: Comparison of effects of uroguanylin, guanylin, Escherichia coli heat-stable enterotoxin in mouse intestine and kidney: Evidence that uroguanylin is an intestinal natriuretic hormone J Invest Med 45: 276-282, 1997
4. Kinoshita H, Fujimoto S, Nakazato M, Yokota N, Date Y, Yamaguchi H, Hisanaga S, Eto T: Urine and plasma levels of uroguanylin and its molecular forms in renal disease. Kidney Int 52: 1028-1034, 1997
5. Fukae H, Kinoshita H, Fujimoto S, Kita T, Nakazato M, Eto T: Changes in urinary levels and renal expression of uroguanylin on low or high salt diets in rats. Nephron 92: 373-378, 2002
6. Carrithers SL, Eber SL, Forte LR, Greenberg RN: Increased urinary excretion of uroguanylin in patients with congestive heart failure. Am J Physiol Heart Circ Physiol 278: H538-H547, 2000
7. Nakazato M, Yamaguchi H, Kinoshita H, Kangawa K, Matsuo H, Chino N, Matsukura S: Identification of biologically active and inactive human uroguanylin in plasma and urine and their increases in renal insufficiency. Biochem Biophys Res Commun 220: 586-593, 1996
8. Forte LR, Fan X, Hamra FK: Salt and water homeostasis: Uroguanylin is a circulating peptide hormone with natriuretic activity. Am J Kidney Dis 28: 296-304, 1996
9. Hoyer JR, Mauer SM, Michael AF: Unilateral renal disease in the rat. Clinical, morphologic, and glomerular mesangial functional features of the experimental model produced by renal perfusion with aminonucleoside. J Lab Clin Med 85: 756-768, 1975
10. +-ATPase activity is correlated with urinary sodium excretion in rat nephrotic syndromes. J Am Soc Nephrol 11: 604-615, 2000
11. Fan X, Wang Y, London RM, Eber SL, Krause WJ, Freeman RH, Forte LR: Signaling pathways for guanylin and uroguanylin in the digestive, renal, central nervous, reproductive, and lymphoid systems. Endocrinology 138: 4636-4648, 1997
12. Ichikawa I, Rennke HG, Hoyer JR, Badr KF, Schor N, Troy JL, Lechene CP, Brenner BM: Role for intrarenal mechanisms in the impaired salt excretion of experimental nephrotic syndrome. J Clin Invest 71: 91-103, 1983
13. Koomans HA: Pathophysiology of oedema in idiopathic nephrotic syndrome. Nephrol Dial Transplant 18[Suppl 6]: vi30-vi32, 2003
14. Perico N, Delaini F, Lupini C, Benigni A, Galbusera M, Boccardo P, Remuzzi G: Blunted excretory response to atrial natriuretic peptide in experimental nephrosis. Kidney Int 36: 57-64, 1989
15. Valentin JP, Qiu C, Muldowney WP, Ying WZ, Gardner DG, Humphreys MH: Cellular basis for blunted volume expansion natriuresis in experimental nephrotic syndrome. J Clin Invest 90: 1302-1312, 1992
16. Valentine JP, Ying WZ, Sechi LA, Ling KT, Qiu C, Couser WG, Humphreys MH: Phosphodiesterase inhibitors correct resistance to natriuretic peptides in rat with Heymann nephritis. J Am Soc Nephrol 7: 582-593, 1996
17. Feraille E, Vogt B, Rousselot M, Barlet-Bas C, Cheval L, Doucet A, Favre H: Mechanism of enhanced Na-K-ATPase activity in cortical collecting duct from rats with nephrotic syndrome. J Clin Invest 91: 1295-1300, 1993
18. Fan X, Hamra FK, Freeman RH, Eber SL, Krause WJ, Lim RW, Pace VM, Currie MG, Forte LR: Uroguanylin: Cloning of preprouroguanylin cDNA, mRNA expression in the intestine and heart and isolation of uroguanylin and prouroguanylin from plasma. Biochem Biophys Res Commun 219: 457-462, 1996
19. Sargent TD, Yang M, Bonner J: Nucleotide sequence of cloned rat serum albumin messenger RNA. Proc Natl Acad Sci USA 78: 243-246, 1981
20. Pedraza-Chaverri J, Cruz C, Chavez MT, Lopez A, Ibarra-Rubio ME, Tapia E, Pena JC: Pathophysiology of experimental nephrotic syndrome induced by puromycin aminonucleoside in rats. II. In vitro release of renin, angiotensinogen and aldosterone. Rev Invest Clin 42: 120-126, 1990
21. Maack T, Park CH, Camargo MJF: Renal filtration, transport, and metabolism of proteins. In: The Kidney: Physiology and Pathophysiology, Vol. 3, edited by Seldin DW, Giebisch G, New York, Raven Press, 1992, pp 3005-3038
22. Sindice A, Basoglu C, Cerci A, Hirsch JR, Potthast R, Kuhn M, Ghanekar Y, Visweswariah SS, Schlatter E: Guanylin, uroguanylin, and heat-stable euterotoxin activate guanylate cyclase C and/or a pertussis toxin-sensitive G protein in human proximal tubule cells. J Biol Chem 277: 17758-17764, 2002
23. Carrithers SL, Hill MJ, Johnson BR, O'Hara SM, Jackson BA, Ott CE, Lorenz J, Mann EA, Giannella RA, Forte LR, Greenberg RN: Renal effects of uroguanylin and guanylin in vivo. Braz J Med Biol Res 32: 1337-1344, 1999
24. Kinoshita H, Fujimoto S, Fukae H, Yokota N, Hisanaga S, Nakazato M, Eto T: Plasma and urine levels of uroguanylin, a new natriuretic peptide, in nephrotic syndrome. Nephron 81: 160-164, 1999
25. Potthast R, Ehler E, Scheving LA, Sindic A, Schlatter E, Kuhn M: High salt intake increases uroguanylin expression in mouse kidney. Endocrinology 142: 3087-3097, 2001
26. Lorenz JN, Nieman M, Sabo J, Sanford LP, Hawkins JA, Elitsur N, Gawenis LR, Clarke LL, Cohen MB: Uroguanylin knockout mice have increased blood pressure and impaired natriuretic response to enterai NaCl load. J Clin Invest 112: 1244-1254, 2003
27. Forte LR: A novel role for uroguanylin in the regulation of sodium balance. J Clin Invest 112: 1138-1141, 2003
28. Min/+ mouse and induces apoptosis in human colon adenocarcinoma cells via cyclic GMP. Cancer Res 60: 5151-5157, 2000